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A B S T R A C T
Cell viability in peripheral blood progenitor cell (PBPC) grafts and its influence on the clinical course following
transplantation was evaluated in 81 consecutive transplantations (72 autologous, 9 allogeneic) performed in patients
with hematological diseases. Viability of cells in PBPC grafts immediately upon collection was 98.6±3.5%, after addition
of dimethyl sulfoxide (DMSO) 73.3±21.8%, and post-thaw 65.2±16.1%. It did not differ significantly between patients
with different diagnoses, gender, age, type of priming used, dose of G-CSF administered or number of CD34+ cells col-
lected. However, grafts stored for more than 60 days showed lower post-thaw viability compared to the ones thawed in the
60 days following cryopreservation (56.6±15.2% vs. 67.6±15.5%, p=0.04). Post-thaw graft viability did not influence
engraftment time, but there was a predisposition towards infectious complications in the post-transplant period in pa-
tients receiving grafts with lower percentage of viable cells. They developed febrile neutropenia more often (72.2% vs. 50%
of patients, p=0.05) and had more febrile days (2.4±2.6 vs. 1.5±2.3, p=0.05) following transplantation. We have demon-
strated that PBPC grafts are capable of long term engraftment regardless of the graft storage time or percentage of viable
cells post-thaw, which confirms the robustness of CD34+ cells during the freeze/thaw procedures carried out in daily
clinical practice. Granulocyte concentration in PBPC grafts could have an influence on infectious complications follow-
ing transplantation and needs to be further investigated on a larger number of patients.
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Introduction
Over the last two decades, the clinical applications of
hematopoietic stem cell transplantation have consider-
ably increased1. Peripheral blood has become a preferred
source of hematopoietic progenitor cells (HPCs) and has
replaced bone marrow for virtually all autologous trans-
plants and for most allogeneic transplants. Advantages
include more rapid engraftment, reduced morbidity and
duration of hospital stay2,3. Both fresh and cryopreserved
peripheral blood progenitor cells (PBPCs) are used for
transplantation. Cryopreserved cells, a standard in auto-
logous setting, are being used more often in the alloge-
neic setting as well4,5. However, the freezing procedure
can be harmful to HPCs and can cause their injury by di-
rect effects of low temperature and by the formation of
ice crystals6. Therefore, a cryoprotectant is needed to
protect the integrity, viability and function of the hema-
topoietic cells during the procedure. Dimethyl sulfoxide
(DMSO) is the most widely used cryoprotectant; it can
penetrate cells, reducing the proportion of water incorpo-
rated into ice and the extent of cellular dehydration7,8. In
spite of all precautions, it is well known that addition of
DMSO, together with cryopreservation and thawing
change the biological characteristics of cells, resulting in
variable loss of cell viability and a reduction in the abso-
lute number of viable CD34+ cells available for trans-
plantation9–13.
The absolute mononuclear cell count was initially
used to predict the engraftment potential of bone ma-
rrow14 until the CD34+ surface antigen, expressed on
early progenitor cells, present on about 1–4% of the
mononuclear cells in the marrow and less than 0.1% in
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peripheral blood, was found to correlate with colony-
-forming capability and engrafting potential of the pe-
ripheral blood HPCs15–17. Recommendation for HPCs
transplant today relies on the CD34+ cell dose, and it is
generally accepted that the minimal acceptable dose for
successful transplantation is 2´106 CD34+ cells per kg of
recipient weight3,18, and 3´106 CD34+ cells per kg of re-
cipient weight for allogeneic transplantation19. Several
studies have demonstrated a correlation between the
number of CD34+ cells infused and predicted engraf-
tment13,20–21. However, the vast majority of studies rely
on pre-cryopreserved CD34+ cell dose, while still little is
known about the quality of the post-thaw product and its
impact on the course of transplantation, since not nearly
as many studies have addressed these questions. A few
studies have shown that the number of viable post-thaw
CD34+ cells infused predicts engraftment in autologous
hematopoietic stem cell recipients13,23. One study has
demonstrated that viable CD34+ stem cell content of a
cord blood graft assessed before transplantation is most
representative of hematologic recovery24.
Prior to transplantation, cell viability of post-thaw
HPCs grafts is often less than 70% which raises concerns
regarding the accuracy of the cell dose and the quality of
the graft that is administered25. However, viability of the
total nucleated cell in post-thaw HPCs grafts does not ac-
curately represent the survival of the CD34+ cells and
no apparent loss of progenitor activity was demonstrated
in most studies26–28. Although it has been reported that
stem cells retain viability and engraftment capacity even
after extended storage in liquid nitrogen29,30, some stud-
ies have demonstrated that prolonged graft storage can
lead to decreased total cell viability in post-thaw HPCs
products31.
The primary aim of this study was to investigate cell
viability in grafts used for autologous and allogeneic pe-
ripheral blood progenitor cell transplantation in patients
with hematological diseases before cryopreservation and
after thawing, and to evaluate the impact of cell viability
on patients’ clinical course following transplantation.
Secondary aims of the study were to evaluate PBPC
mobilization efficacy in this group of patients and to cor-
relate the CD34+ cell dose infused with hematopoietic
recovery following transplantation.
Material and Methods
Mobilization and collection
Peripheral blood progenitor cell grafts used for 81
consecutive transplantations from January 2007 to June
2009 in Department of Medicine, University Hospital
»Merkur« were included in this study. Nine PBPCs used
for allogeneic transplantation were obtained from re-
lated donors, and the remaining 72 were collected for
autologous transplantations from patients with different
hematological diseases. Characteristics of patients in-
cluded in this study are summarized in Table 1. Autolo-
gous PBPCs were mobilized with chemotherapy and
granulocyte colony stimulating factor (G-CSF). All mye-
loma patients received cyclophosphamide 3 g/m2 as
priming. Out of 45 lymphoma patients, 37 received mini-
BEAM (carmustin 60 mg/m2 on day 1, ara-c 2´100 mg/m2
from day 2 to 5, etoposide 75 mg/m2 from day 2 to 5,
melphalan 30 mg/m2 on day 6), while 8 patients received
other chemotherapeutic regimen. The majority of pa-
tients with acute leukemia (8/13) received high dose
ara-c 2´1g/m2 day 1 to 6 and mitoxantron 10 mg/m2 from
day 5 to 7. Lymphoma and myeloma patients were dis-
charged after chemotherapy, only to be readmitted 9 days
later. G-CSF was administered at 10 mcg per kg of body
weight per day, starting either on the day when WBC
counts decreased to levels <1´109/L, or, if this did not oc-
cur, one day after WBC count nadir. G-CSF was contin-
ued until leukapheresis, which was initiated when the
blood CD34+ count was at least 10´106/L. PBPCs from
related donors were in all cases mobilized with G-CSF
(10 mcg per kg of body weight ´ 5 days). Cell collection
procedures were performed with a continuous flow blood
cell separator (COBE Spectra, Lakewood, USA). All cell
collection procedures were performed with program ver-
sion 6.1.
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TABLE 1
PATIENTS’ CHARACTERISTICS
Total number 81
Gender
Male 40
Female 41
Age
Median 47.5
Range 19–71
Diagnosis
Non Hodgkin’s Lymphoma 35
Multiple Myeloma 20
Hodgkin’s Disease 10
Acute Myeloid Leukemia 7
Acute Lymphoblastic Leukemia 6
Aplastic Anemia 2
Prolymphocytic Leukemia 1
Previous Treatment
Lines of chemotherapy Median 2
Range 1–7
Cycles of chemotherapy Median 7
Range 1–17
Type of Transplantation
Autologous 72
Allogeneic 9
CD34+ cells (´106/kg) infused
Mean 12.7
Range 1.6–84.2
Mononuclear cells (´108/kg) infused
Mean 6.9
Range 1.1–20.7
CD34+ enumeration
Absolute numbers of CD34+ cells were enumerated
immediately following harvest. Analysis of CD34+ cells
was performed on flow cytometer (Coulter Epics XL,
Fullerton, USA) according to the manufacturer’s in-
structions with the commercially available CD34 anti-
body (BD Bioscience, San Jose, USA).
Cryopreservation and thawing
Hematopoietic progenitor cells were cryopreserved at
a concentration of 2–3´108 total nucleated cell permillili-
ter to –160 °C by a controlled rate freezer (Planer Kryo
560–16, Sunbery on Thames, UK) in a final concentra-
tion of 10% dimethyl sulfoxide (DMSO) (WAK Chemie
Medical GmbH, Steinbach, Germany) and 4.5% human
serum albumin. The controlled-rate freezing started at
12 °C. In the first step of the run, the chamber was cooled
to +4 °C at a rate of 4 °C per minute; This temperature
was held for 5 minutes. This was followed by a cool-
ing-rate of 2 °C perminute down to –5 °C. Further cooling
was performed with 1 °C permin down to –40 °C, and the
procedure was completed by a final cooling rate of 5 °C
permin down to a temperature of –160 °C. After the cryo-
preservation procedure, grafts were stored in liquid ni-
trogen at –196 °C. On the day of transplantation they
were thawed in a water bath at 37 °C for 1–3 min. A sam-
ple of 1 ml was taken for viability analysis just before
transplantation. No additional washing was performed
and all testing was performed on samples from the com-
plete products.
Viability measurement
The viability assay was performed using trypan blue
dye exclusion test. Non viable cells, due to damage to the
integrity of their membrane, are stained blue by the dye
and can be identified under a light microscope. Trypan
blue 0.1% solution (Sigma, St. Louis, USA) was diluted
with an equal volume of cells. At least 200 cells were mi-
croscopically analyzed in duplicate for viability in a he-
mocytometer chamber. Analysis was performed immedi-
ately with a single observer for all samples. Viability was
calculated as the mean percentage of viable cells of the
two analyses. Cell viability in PBPC grafts was assessed
at 3 timepoints: 1. immediately after cell collection, 2. be-
fore cryopreservation, after addition of DMSO, and 3. im-
mediately after thawing.
Conditioning, engraftment and supportive care
Patients received high-dose chemotherapy appropri-
ate for the disease prior to PBPC infusion. Conditioning
regimen included BEAM (carmustin 300 mg/m2 on day
–6, ara-c 2´200 mg/m2 from day –5 to –2, etoposide 200
mg/m2 from day –5 to –2, melphalan 140 mg/m2 on day
–1), high dose melphalan (100 mg/m2 from day –4 to –3),
BuCy (busulfan 4 mg/kg from day –8 to –5 and cyclo-
phosphamide 60 mg/kg from day –4 to –3), Flu-BU-ATG
(fludarabine 30 mg/m2 day –10 to –5, busulfan 4 mg/kg
day –6 to –5, ATG day –4 to –1. Peripheral blood progeni-
tor cell grafts were infused into patients through central
venous catheters in 30–45 min. Routine peripheral blood
cell counts were performed daily. using an automated he-
matology analyzer (Sysmex XE-2100, Kobe, Japan). Two
independent parameters were used to determine the
time to engraftment post-transplant. These included the
first day out of 2 sequential days post-transplant in
which an absolute neutrophil count (ANC) of 1´109/L
was achieved, and the first day out of 2 in which 20´109/L
platelets were achieved without transfusion. All patients,
except patients with acute myeloid leukemia in the auto-
logous setting, received G-CSF 10 mcg/kg/day during
neutropenia following transplantation. Ciprofloxacin
2´250 mg and fluconazole 200 mg were given orally as
antiinfective prophylaxis. Body temperature was moni-
tored every 2h; in case of fever 38.5 °C or 38 °C in two
consecutive measurements microbiological work-up was
done and empirical antimicrobial treatment was started.
In the absence of other clinical reasons for patients’
transfusion support, two units of packed red cells were
transfused in all cases when the hemoglobin was less
than 75 g/L and 8 units of random donor platelets if
platelets were less than 5´109/L.
Statistical analysis
Analysis included descriptive statistics, with data ex-
pressed as mean±standard deviation, unless otherwise
indicated. Standard regression analysis was used to de-
termine possible correlations between variables. Chi squ-
are, t-test and the nonparametric Mann-Whitney and
Kruskal-Wallis tests were used to assess for statistical
differences between two or more groups. A p value less
than 0.05 was considered statistically significant. All sta-
tistical analyses were performed with StatViewTM statis-
tical program, version 5.0.1. (SAS Institute, Cary, NC,
USA).
Results
Sufficient number of PBPCs for one transplantation
(>2´106 and >4´106 CD34+ cells per kg of patient’s BW
for autologous and allogeneic transplantation, respec-
tively) was collected during a single apheresis in 56/72
patients and in 2/9 related donors. In 12 patients and 6
donors, 2 aphereses were needed and in 4 patients and 1
donor, 3 aphereses were necessary to achieve this goal.
HPCs mobilization was suboptimal in 2 patients with
multiple myeloma: 1.64 and 1.95´106 CD34+ cells per kg
of BW were collected. Although target CD34+ cell dose
was not collected in these patients, clinical decision was
to use these grafts for transplantation.
As part of the PBPC collection procedure for auto-
logous transplantation, G-CSF was administered for a
median of 7.5 days (mean 7.6±1.4, range 4–11) at a median
dose of 4350 mcg (mean 4575±990, range 2400–9000).
PBPCs collection was most successful in patients with
lymphoma, which is why they received a higher CD34+
cell dose following high dose chemotherapy conditioning
than patients with multiple myeloma or acute leukemia
(15.9±14.8 vs. 8.6±5.9 vs. 8.8±9.1, respectively. Kruskal-
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-Wallis, p=0.03). Mean numbers of CD34+ and mononu-
clear cells infused for all patients were 12.7±12.6´106 and
6.9±4.6´108 per kg of body weight, respectively (Table 1).
There was no correlation between the number of CD34+
cells collected and age, gender or number of lines/cycles
of previous therapy received.
A strong, statistically significant correlation was found
by simple regression between pre-cryopreserved CD34+
cell dose and hematopoietic recovery in patients, ex-
pressed as time to reach ANC>1´109/L and platelets
>20´109/L (R2=0.14 p=0.001, R2=0.12 p=0.005, respec-
tively. This was confirmed when patients were divided in
two groups according to pre-cryopreserved CD34+ cell
dose, the cutoff point being the median value of 9.4´106
per kg of body weight (Mann Whitney, ANC recovery
p<0.0001, platelet recovery p=0.0005). Occurrence of fe-
brile neutropenia and total number of febrile days did
not differ significantly between patients depending on
the dose of CD34+ cells infused.
Viability of the cells in PBPC grafts was found to be
different at the three predetermined timepoints (Figure
1). Immediately upon collection, mean cell viability was
98.6±3.5%, after addition of DMSO 73.3±21.8, and post-
-thaw 65.2±16.1%. Mean graft storage time was 105.9±246
days with a median of 40.5 days.
Post-thaw viability of the grafts did not differ signifi-
cantly between patients with different diagnoses, gender,
type of priming used or dose of G-CSF administered.
Also, no correlation was found between post-thaw viabil-
ity and patients age or number of collected CD34+ cells.
However, graft storage time was found to influence post-
-thaw viability of HPCs grafts (Figure 2); grafts stored
for more than 60 days showed lower post-thaw viability
compared to the ones thawed in the 60 days following
cryopreservation (56.6±15.2 vs. 67.6±15.5, Mann Whit-
ney p=0.04). Mean graft storage time for myeloma pa-
tients was somewhat longer compared to graft storage
time for patients with other diagnoses, but these differ-
ences did not reach statistical significance.
Median time post-transplantation to reach absolute
neutrophil counts >1´109/L and platelets >20´109/L in
two consecutive days was 10 and 11 days, respectively.
Patients on average received 401±657.3 ml of packed
RBC and 11.5±13.4 doses of platelet transfusions. In or-
der to evaluate not only the effect of CD34+ dose (see
above) but also the influence of post-thaw graft viability
on engraftment time we have correlated post-thaw via-
bility with time to reach target ANC and platelet counts
and have not found significant correlations by simple
regression (Figure 3a and b). Additionally, two equal
groups (»low« and »high« post-thaw viability grafts) were
formed, using the median viability observed in the whole
group (65%) as the cutoff point. Hematopoietic recovery
(time to ANC>1´109 and platelets 20´109/L) as well as
need for transfusions was not found to be significantly
different between the two groups.
Data on infectious complications in the post-trans-
plant period were available for 72 patients. We have dis-
covered a clear predisposition towards infectious compli-
cations in patients receiving grafts with lower percentage
of viable cells. These patients developed febrile neutro-
penia more often than patients receiving grafts with
higher post-thaw viability [72.2% of patients vs. 50% of
patients, c2 (p=0.05), Figure 4 and also differed in num-
ber of febrile days observed (2.4±2.6 vs. 1.5±2.3, Mann
Whitney p=0.05). Furthermore, post-thaw viability values
were found to correlate by simple regression (R2=0.06,
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Fig. 1. Viability of cells in PBPC grafts assessed by trypan blue
exclusion test: a) after collection b) after addition of DMSO, prior
to cryopreservation c) post-thaw. Statistical differences between
A, B and C were assessed with paired t-test. The lower and the
upper lines of the box show the 25th and 75th percentiles. The line
within the box is the median value, the whiskers show the 10th
and 90th percentiles. Black dots represent the outliers.
Fig. 2. Post-thaw viability of cells in PBPC grafts according to
duration of graft storage time The lower and the upper lines of
the box show the 25th and 75th percentiles. The line within the
box is the median value, the whiskers show the 10th and 90th per-
centiles. Black dots represent the outliers.
p=0.003, Figure 3b) with number of febrile days ob-
served in the post-transplant period. The influence of
other relevant factors for occurrence of febrile neutrope-
nia (CD34+ cell dose, patients’ age, diagnosis, auto-
logous or allogeneic transplantation, number of lines/cy-
cles of therapy received prior to transplantation) has also
been investigated. Compared to patients with lymphoma
or myeloma, patients suffering from acute leukemia had
a significantly higher incidence of febrile neutropenia
(c2-p=0.001) following transplantation. Influence of ot-
her previously mentioned parameters on development of
febrile neutropenia was not statistically significant.
Discussion
The mobilization scheme, developed and applied in
our hospital with G-CSF administered according to a
modulating schedule, resulted in mobilizing sufficient
numbers of CD34+ cells in the vast majority of our pa-
tients. It can be considered both economical and success-
ful, with fewer days of hospitalization needed and total
dose of filgrastim used lower than usually reported32. It
is well known that prior use of stem cell toxic agents,
such as nitrogen mustard, procarbazine, melphalan, car-
mustine or high-dose cytarabine can result in poor and
unpredictable mobilization33. The use of miniBEAM as
priming regimen in our lymphoma patients, although
controversial for previously mentioned reasons, did not
affect stem cell mobilization potential, and as we have re-
ported previously, was more successful in yielding suffi-
cient CD34+ numbers compared to the scheme with cy-
clophosphamide used for priming34,35. The lack of signifi-
cant stem cell toxicity of miniBEAM observed in our pa-
tients can probably be explained by the fact that it was
administered to these patients for the first time. The
choice of miniBEAM for priming brought an additional
benefit, providing instant and »in vivo« information about
chemosensitivity of the lymphoma to this combination of
drugs, used later in higher doses for myeloablative condi-
tioning.
In our patients, as in a number of other studies13, 20–22,
faster hematopoietic recovery was observed in patients
that received a higher CD34+ cell dose. No correlation
was found with the CD34+ dose and the occurrence of fe-
brile neutropenia or number of febrile days in the post-
-transplant period, which is also in concordance with
other published results36.
We assessed PBPC viability using trypan blue dye ex-
clusion test, which remains the most common membrane
integrity stain used to distinguish between viable and
nonviable nucleated cells. This test was used, sometimes
in combination with other tests, in most of the other re-
ported studies26, 37–39. The fact that we have evaluated vi-
ability of not only CD34+ cells, but all cells in the PBPC
graft has to be underlined and taken into account when
comparing our results with the results of other studies.
Namely, due to their different membrane content of li-
pids and proteins, HPCs appear to be more resistant to
cryopreservation injury than other mononuclear cells25,27,28
which is reflected, post-thaw, in their higher viability
compared to the viability of all nucleated cells. Determi-
nation of PBPC graft viability after thawing takes into
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Fig. 3. Post-thaw viability of cells in PBPC grafts in relation to
post-transplant clinical course: A – number of days needed to
reach absolute neutrophil counts (ANC) >1´109/L, B – number of
days needed to reach platelet counts >20´109/L, C – number of
febrile days.
Fig. 4. Incidence of febrile neutropenia in patients following
hematopoietic stem cell transplantation according to post-thaw
viability of cells in PBPC grafts.
account the effects of freezing, thawing and DMSO, and
therefore represents the actual composition of the graft
prior to (re)infusion. Therefore, for the purpose of corre-
lating PBPC viability with clinical data, in our study we
have chosen post-thaw viability results (Figure 1c) as the
most relevant ones.
Cell viability in PBPCs grafts registered at the prede-
termined timepoints in our study showed the expected
decreasing trend from the time of collection to post-thaw.
Similar results with loss of viability of both total nucle-
ated and CD34+ cells in post thaw samples compared
with fresh samples were observed by other investigators
as well23,26,30,37,40. We, as others, have also found impor-
tant inter-patient differences of graft viability, especially
at the second and third timepoint (Figures 1b and c). PBPC
graft viability after addition of DMSO prior to cryopre-
servation ranged in our study from 24% to 100%, and
post-thaw from 20.4% to 94.4%. No correlation was found
between viability and the number of CD34+ cells present
in grafts, patients’ age, gender, diagnosis or extent of pre-
vious treatment, but contrary to observations from some
other studies30,41, we have found that grafts stored for
more than 60 days had lower post-thaw viability. Gen-
erally, storage time of most stem cell grafts is less than 3
months (in our study: mean 105±246 days, median 40.5
days). The question of graft durability, defined as the
time that stem cells can safely remain cryopreserved still
remains somewhat controversial42,43. However, most of
the studies have demonstrated that even PBPC grafts
that have been stored for several years are capable of
long term engraftment44,45. Our results confirm these
findings, since all our patients engrafted, regardless of
their graft storage time or percentage of viable cells
post-thaw.
The design of our study did not envision quantifica-
tion of CD34+ cells after cryopreservation, nor their via-
bility assessment pre- and post-thaw. These procedures
are still not routinely performed in the vast majority of
transplant centers. Some authors have shown that quan-
tification of post-thaw viable CD34+ cells seems to be
the most valuable predictor of platelet engraftment13,23
One could therefore argue that assessing CD34+ viabil-
ity at different stages of processing could, besides provid-
ing accurate quality control, maybe help in identifying
patients at risk of delays in hematopoietic reconstitution
and alter some aspects of their care following transplan-
tation. However, our results question the necessity of
performing these controls, confirming the relative ro-
bustness of CD34+ cells during the freeze/thaw proce-
dures which are carried out in daily clinical practice.
An interesting and, to our knowledge previously un-
reported phenomenon was found regarding PBPC graft
post-thaw viability and infectious complications in pa-
tients following transplantation. Namely, patients with
higher PBPC graft viability were less prone to develop fe-
brile neutropenia and had less febrile days in the post-
-transplant period (Figures 3c and 4).
It has been demonstrated that granulocytes collected
after the administration of G-CSF seem to retain func-
tional and biochemical characteristics for at least 24
hours of storage, which suggests additional effects of
G-CSF mobilization beyond enhancing yields and the
possibility of storage of these components after colle-
ction46. However, the tolerance of granulocytes to DMSO
is lower than that of lymphocytes or immature HPCs47
and a number of studies have shown that the majority of
cells lost during cryopreservation are granulocytes, while
most lymphocyte-like cells, including CD34+ cells sur-
vive the process of freezing and thawing12,26,48. There
have been publications that claim successful cryopreser-
vation of granulocytes but huge variations are found be-
tween results depending on the viability assay used49. Vi-
ability tests usually reflect an intact cell membrane,
while they do not provide information on typical granu-
locytic functions such as chemotaxis or bactericidal activ-
ity and are therefore limited in their ability to predict
what is going to happen in vivo. Fois and colleagues have
shown that post-thaw cell viability is inversely correlated
with the granulocytic cell concentration before cryopre-
servation30. Not knowing the granulocyte concentration
before and after thawing in our samples, we can only
speculate that those grafts showing low post-thaw via-
bilty could have had high pre-thaw concentrations of
fragile granulocytes, vulnerable to cryopreservation and
thawing. On the contrary, those grafts showing high post-
-thaw viability could have had either lower pre-thaw
granulocyte concentrations, or more robust granulocytes,
that might have survived cryopreservation and thawing
and that might have, to some extent, contributed to pro-
tection of those patients from infections in the post-
-transplant period. Knowing the short half-life of granu-
locytes, and their relatively low total dose in the PBPC
graft, this explanation remains highly speculative. How-
ever, it is an intriguing finding that deserves further in-
vestigation with additional tests, on a larger number of
patients, less heterogeneous in terms of underlying disease,
type of transplantation or conditioning regimen used.
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VIJABILNOST PRIPRAVKA KRVOTVORNIH MATI^NIH STANICA NAKON ODMRZAVANJA: IMA LI
KLINI^KO ZNA^ENJE ILI NE?
S A @ E T A K
Vijabilnost pripravka krvotvornih mati~nih stanica iz periferne krvi (KMSPK) i njen utjecaj na klini~ki tijek nakon
transplantacije istra`ivani su kod 81 uzastopne transplantacije (72 autologne i 9 alogeni~nih) provedene u bolesnika
oboljelih od hematolo{kih bolesti. Vijabilnost stanica KMSPK odmah nakon sakupljanja bila je 98,6±3,5%, nakon dodatka
dimetil sulfoksida 73,3±21,8%, a nakon odmrzavanja 65,2±16,1%. Nije se bitno razlikovala kod bolesnika razli~itih
dijagnoza, dobi, spola, na~ina na koji su KMSPK mobilizirane, dozi G-CSFa ili broju prikupljenih CD34+ stanica. Pri-
pravci zamrznuti dulje od 60 dana imali su slabiju vijabilnost nakon odmrzavanja u usporedbi s onima koji su bili
zamrznuti manje od 60 dana (56,6±15,2% prema 67,6±15,5%, p=0,04). Vijabilnost nakon odmrzavanja nije utjecala na
dinamiku hematopoetskog oporavka, no kod bolesnika kojima je vijabilnost pripravka KMSPK bila slabija uo~ena je
sklonost infektivnim komplikacijama. ^e{}e su razvili febrilnu neutropeniju (72,2% prema 50% bolesnika, p=0,05) te
su imali vi{e febrilnih dana (2,4±2,6 prema 1,5±2,3, p=0,05) nakon transplantacije. Pokazali smo da transplantacija
KMSPK dovodi do hematopoetskog oporavka neovisno o tome koliko je dugo pripravak KMSPK bio zamrznut i neovi-
sno o vijabilnosti stanica nakon odmrzavanja. Time se potvrdila otpornost CD34+ stanica na postupke zamrzavanja i
odmrzavanja koji se rutinski provode u svakodnevnoj praksi. Mogu}e je da koncentracija granulocita u pripravku KMSPK
ima utjecaj na razvoj infektivnih komplikacija nakon transplantacije, no taj je fenomen potrebno detaljnije istra`iti na
ve}em broju bolesnika.
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